A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
← catalyst calendarNCT06730750 · readout in 17 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
360estimated
Sites
6
Countries
Australia, Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-12 | actual | When the study began enrolling |
| Primary completion | 2026-09-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-09 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: BMS-986490
- Drug: Bevacizumab
Primary outcomes
what the primary-completion date above is the date OFNumber of participnats with Adverse Events (AEs)
measured Up to 100 days following discontinuation of dosing
Number of participants with Serious AEs (SAEs)
measured Up to 100 days following discontinuation of dosing
Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteria
measured Up to 28 days after the first treatment of study intervention
Number of participants with AEs leading to discontinuation
measured Up to 100 days following discontinuation of dosing
Number of deaths
measured Up to 100 days following discontinuation of dosing
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed